
Opinion|Videos|July 3, 2024
Evolving Treatment Paradigm and NCCN Guideline Updates
Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm.
Advertisement
Episodes in this series

- Dr. Freedland asks Dr. Efstathiou: Please review the current treatment landscape for CSPC. What are the main therapeutic approaches typically utilized for these patients?
- What role does androgen deprivation therapy alone play, and in what settings?
- When are chemotherapy and novel hormonal agents like enzalutamide considered?
- How do you sequence or combine these different modalities in your practice?
- Dr. Efstathiou asks Dr. Freedland:The NCCN guidelines were recently updated to include enzalutamide as a treatment option for high-risk non-metastatic CSPC and metastatic CSPC, as well as metastatic and nonmetastatic CRPC. Can you summarize the significance of these updates?
- How do you see these guideline changes impacting clinical practice patterns?
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
4
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
5

